Search results
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance· 2 hours agoNurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher...
... of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the...
Benzinga· 3 days agoNurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...
Biotech With 345% Run Posts A 'Clear Win' In Cancer Treatment
Investor's Business Daily· 2 days agoThe company tested its treatment, dubbed NX-5948, in patients with relapsed or refractory forms of ...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThis trial evaluated the efficacy of AbbVie/Roche's Venclexta (venetoclax) and BeiGene's Brukinsa...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 2 days agoMB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center to treat...
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks· 1 day agoFree Report) reported updated results from a cohort of an ongoing phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (WM), a rare form ...
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the...
NewMediaWire via Yahoo Finance· 1 day ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen,...
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket...
Benzinga· 2 days agoShares of Nurix Therapeutics, Inc. NRIX rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory ...
Galapagos (NASDAQ:GLPG) Hits New 52-Week Low at $25.95
ETF DAILY NEWS· 4 days agoGalapagos NV (NASDAQ:GLPG – Get Free Report) reached a new 52-week low during trading on Thursday . The company traded as low as $25.95 and last traded at $26.01, with a volume of 8834 shares ...
Head to Head Survey: Evaxion Biotech A/S (NASDAQ:EVAX) and Halozyme Therapeutics (NASDAQ:HALO)
ETF DAILY NEWS· 5 days agoHalozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the ...